The Prevalence of the Potential Drug-Drug Interactions  Involving Anticancer Drugs in China: A Retrospective Study

Wang, Weilan; Xiao, Bingkun; Liu, Ziqi; Wang, Dongxiao; Zhu, Man

doi:10.18502/ijph.v48i3.886

Cited by 5 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Brazil, it is known that there is wide use of herbal medicines and medicinal plants, which is due to historical and cultural aspects and to the broad availability of species in our country. Thus, many patients reported drinking teas to manage adverse reactions during chemotherapy treatment 11,18 . This is relevant information for the entire multiprofessional team identified in this study, as the therapeutic index of antineoplastic chemotherapeutics is oftentimes narrow and herbal medicines and medicinal plants can alter the expression of several enzymes related to the biotransformation of medications; therefore, drug interactions can have undesirable consequences and may even compromise the person's life in some cases 19 .…”

Section: Resultsmentioning

confidence: 99%

“…They can occur throughout the treatment and can be with medications that were already used by the patient and/or others that are added during course of the treatment. This issue is of major importance due to the intrinsic characteristics of chemotherapy drugs, such as their narrow therapeutic index and, therefore, drug interactions can increase toxicity or decrease their effectiveness, compromising treatment and patient safety 11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Conciliação medicamentosa farmacêutica em pacientes ambulatoriais com câncer de mama em um hospital de Ensino

ALMEIDA,

SANTOS,

DE ANDRADE

et al. 2023

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

Objetivo: definir o perfil farmacoterapêutico, interações medicamentosas e intervenções farmacêuticas, reações adversas em pacientes com câncer de mama em uso quimioterapia endovenosa submetidos ao serviço de conciliação medicamentosa farmacêutica. Métodos: caracterizase como observacional transversal sendo submetido e aprovado pelo Comitê de ética, com o número CAAE: 66439017.3.0000.5546. Foram coletados dados a partir das fichas de conciliação medicamentosa e dados de planilhas do serviço de farmácia cínica. Resultados: Foram analisadas 31 conciliações medicamentosas farmacêuticas no período de setembro a outubro de 2022, de um total de 70 pacientes com câncer de mama em quimioterapia endovenosa. A maioria dos pacientes, 97% (n=30) eram mulheres, a média de idade foi 52,51 anos. Quanto a escolaridade, apenas 32,3% (n=10) tinham ensino médio completo. O protocolo AC-T (Doxorrubicina, ciclofosfamida e paclitaxel) foi o mais utilizado (38,7% n=12). A maioria dos pacientes 67,7% (n=21) tinham outras comorbidades sendo hipertensão arterial a mais comum. A média de medicamentos em uso contínuo por paciente foi de 3,38, sendo que 45,2% (n=14) usavam 4 ou mais medicamentos o que caracteriza polifarmácia, além do uso de chás medicinais que foi identificado em 50% (n=12) dos pacientes. Encontrou-se discrepâncias nessas conciliações medicamentosas em 83,9% (n=26) dos pacientes. Além disso, foram observadas 91 interações medicamentosas, sendo uma média de 2,9 interações por paciente. Em relação as intervenções farmacêuticas foram identificadas 24 possíveis intervenções, apresentando uma média de 0,77 intervenções por paciente. A maioria dos pacientes (61,3% n=19) apresentou alguma reação adversa desde a última sessão de quimioterapia. Conclusão: os resultados reforçam a importância do profissional farmacêutico e da reconciliação medicamentosa em pacientes ambulatoriais garantindo a segurança e efetividade dos tratamentos.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Conciliação medicamentosa farmacêutica em pacientes ambulatoriais com câncer de mama em um hospital de Ensino

ALMEIDA,

SANTOS,

DE ANDRADE

et al. 2023

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

show abstract

“…41 A Chinese study reported a 97.02% severity level of drug-drug interactions in cancer patients. 51 In addition, 67% severe and 26.9% moderate drug-drug interactions were observed among cancer patients undergoing chemotherapy. 52 The findings of the current study suggested a higher incidence of potential drug-drug interactions among gastrointestinal cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Drug-related problems among esophageal, gastric and colorectal cancer patients at the National and referral hospital in Kenya

Degu

Karimi

Opanga

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Cancer therapy has remarkable potential for drug-related problems due to the high cytotoxicity and narrow therapeutic index of most anti-neoplastic regimens. However, there is a lack of comprehensive studies on drug-related problems in patients with gastrointestinal cancer in Kenya. Therefore, the present study aimed to investigate the prevalence, types and predictors of drug-related problems among gastrointestinal cancer patients at Kenyatta National Hospital. Methods A cross-sectional study was used to assess the prevalence of drug-related problems among a random sample of 160 esophageal, 103 gastric, and 96 colorectal cancer patients. Data were collected using a researcher-administered questionnaire and data abstraction tool after training the data collectors. Patient-specific details such as socio-demographic features, histological cancer types, cancer stage, comorbidity types, and treatment regimen were recorded after the review of medical records and patient interviews. The potential of drug-related problems was determined as per the standard guidelines. The data were entered and analysed using version 26.0 SPSS statistical software. Results Most esophageal (51.9%), gastric (59.2%), and colorectal (62.5%) cancer patients had a high prevalence of drug-related problems. The need for additional drug therapy and adverse drug reactions were the predominant categories of drug-related problems. Most adverse drug reactions identified had possible categories of causality score, mild severity levels, and definitely preventable types of adverse drug reactions among all gastrointestinal cancer patients. Comorbidity and advanced-stage disease were significant predictors of drug-related problems. Conclusions Drug-related problems were prevalent among gastrointestinal cancer patients in our setting. Comorbidity and advanced stages of disease were significant predictors of drug-related problems.

show abstract

“…DDI, which causes 4% of cancer death, is of major concern in oncology [ 5 ]. This is owing to the inherent toxicity/narrow therapeutic index of anticancer agents, their intra- and inter-individual variability, and their simultaneous administration along with different drugs to cancer patients [ 6 – 11 ]. DDI can be manifested at the pharmacokinetic (PK) and/or the pharmacodynamics (PD) level or a combination of mechanisms of the drug itself or a combination of drugs [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Ceftazidime and cefepime antagonize 5-fluorouracil’s effect in colon cancer cells

et al. 2022

View full text Add to dashboard Cite

Background Drug-drug interaction (DDI), which can occur at the pharmacokinetics and/or the pharmacodynamics (PD) levels, can increase or decrease the therapeutic or adverse response of a drug itself or a combination of drugs. Cancer patients often receive, along their antineoplastic agents, antibiotics such as ß-lactams to treat or prevent infection. Despite the narrow therapeutic indices of antibiotics and antineoplastic agents, data about their potential interaction are insufficient. 5-fluorouracil (5-FU), widely used against colon cancer, is known for its toxicity and large intra- and inter- individual variability. Therefore, knowledge about its interaction with antibiotics is crucial. Methods In this study, we evaluated at the PD levels, against HCT-116 colon cancer cells, DDI between 5-FU and several ß-lactams (ampicillin, benzypenicillin, piperacillin, meropenem, flucloxacillin, ceftazidime (CFT), and cefepime (CFP)), widely used in intensive care units. All drugs were tested at clinically achieved concentrations. MTT assay was used to measure the metabolic activity of the cells. Cell cycle profile and apoptosis induction were monitored, in HCT-116 and DLD-1 cells, using propidium iodide staining and Caspase-3/7 activity assay. The uptake of CFT and CFP by the cells was measured using LC-MS/MS method. Results Our data indicate that despite their limited uptake by the cells, CFT and CFP (two cephalosporins) antagonized significantly 5-FU-induced S-phase arrest (DLD-1 cells) and apoptosis induction (HCT-116 cells). Remarkably, while CFP did not affect the proliferation of colon cancer cells, CFT inhibited, at clinically relevant concentrations, the proliferation of DLD-1 cells via apoptosis induction, as evidenced by an increase in caspase 3/7 activation. Unexpectedly, 5-FU also antagonized CFT’s induced cell death in DLD-1 cells. Conclusion This study shows that CFP and CFT have adverse effects on 5-FU’s action while CFT is a potent anticancer agent that inhibits DLD-1 cells by inducing apoptotic cell death. Further studies are needed to decipher the mechanism(s) responsible for CFT’s effects against colon cancer as well as the observed antagonism between CFT, CFP, and 5-FU with the ultimate aim of translating the findings to the clinical settings.

show abstract

The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study

Cited by 5 publications

References 35 publications

Conciliação medicamentosa farmacêutica em pacientes ambulatoriais com câncer de mama em um hospital de Ensino

Conciliação medicamentosa farmacêutica em pacientes ambulatoriais com câncer de mama em um hospital de Ensino

Drug-related problems among esophageal, gastric and colorectal cancer patients at the National and referral hospital in Kenya

Ceftazidime and cefepime antagonize 5-fluorouracil’s effect in colon cancer cells

Contact Info

Product

Resources

About